Association of Vascular Risk Factors and Cerebrovascular Pathology With Alzheimer Disease Pathologic Changes in Individuals Without Dementia
In a large nondemented population, our findings suggest that cSVD is a mediator of the relationship between VRFs and CSF Aβ<sub>1-42</sub> and affects downstream neurodegeneration and cognitive impairment. We provide evidence of VRFs indirectly affecting the pathogenesis of AD, highlighting the importance of considering cSVD burden in memory clinics for AD risk evaluation and as an early window for intervention. These results stress the role of VRFs and cerebrovascular pathology as key biomarkers for accurate design of anti-amyloid clinical trials and offer new perspectives for patient stratification.
Authors
- Lyduine E. Collij (ORCID: https://orcid.org/0000-0001-6263-1762)
- Silvia Ingala (ORCID: https://orcid.org/0000-0003-2199-385X)
- Carol Di Perri
- Joanna Marguerite Wardlaw (ORCID: https://orcid.org/0000-0002-9812-6642)
- Gaël Chételat (ORCID: https://orcid.org/0000-0002-4889-7932)
- John T. O’Brien (ORCID: https://orcid.org/0000-0002-0837-5080)
- Nick C. Fox (ORCID: https://orcid.org/0000-0002-6660-657X)
- Luigi Lorenzini (ORCID: https://orcid.org/0000-0002-9756-881X)
- Kaj Blennow (ORCID: https://orcid.org/0000-0002-1890-4193)
- Philip Scheltens (ORCID: https://orcid.org/0000-0002-1046-6408)
- Mario Tranfa (ORCID: https://orcid.org/0000-0002-4451-4746)
- Vincenzo Silani (ORCID: https://orcid.org/0000-0002-7698-3854)
- Pieter Jelle Visser (ORCID: https://orcid.org/0000-0001-8008-9727)
- Craig Ritchie (ORCID: https://orcid.org/0000-0002-6202-6906)
- Henk J. M. M. Mutsaerts (ORCID: https://orcid.org/0000-0003-0894-0307)
- Michael Ewers (ORCID: https://orcid.org/0000-0001-5231-1714)
- Carole H. Sudre (ORCID: https://orcid.org/0000-0001-5753-428X)
- Pierre Payoux (ORCID: https://orcid.org/0000-0002-1374-1620)
- Nicola Ticozzi (ORCID: https://orcid.org/0000-0001-5963-7426)
- Pablo Martínez‐Lage
- Sven Haller (ORCID: https://orcid.org/0000-0001-7433-0203)
- Adam Waldman (ORCID: https://orcid.org/0000-0003-4398-6431)
- Alessio Maranzano (ORCID: https://orcid.org/0000-0002-3642-9584)
- Frederik Barkhof (ORCID: https://orcid.org/0000-0003-3543-3706)
- Federico Verde (ORCID: https://orcid.org/0000-0002-3977-6995)
- Juan Domingo Gispert (ORCID: https://orcid.org/0000-0002-6155-0642)
- Daisy Mollison (ORCID: https://orcid.org/0000-0001-6548-0103)
- Alle Meije Wink (ORCID: https://orcid.org/0000-0002-8197-0118)
- Adam James Schwarz (ORCID: https://orcid.org/0000-0002-9743-6171)
- Christopher Foley (ORCID: https://orcid.org/0000-0002-7319-2539)
- Robin Wolz (ORCID: https://orcid.org/0009-0002-5856-0126)
- Giovanni B. Frisoni (ORCID: https://orcid.org/0000-0001-7075-7082)
- Betty M. Tijms
Institutions
- Uppsala University (SE)
- Lund University (SE)
- Amsterdam Neuroscience (NL)
- Federico II University Hospital (IT)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Neurology
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1212/wnl.0000000000209801
- Citations
- 20
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 7.71
Funders
- Eli Lilly and Company
- Biogen
- European Federation of Pharmaceutical Industries and Associations
- European Commission
- Eisai
- Novo Nordisk
- Medical Research Council